RU2019131098A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2019131098A3 RU2019131098A3 RU2019131098A RU2019131098A RU2019131098A3 RU 2019131098 A3 RU2019131098 A3 RU 2019131098A3 RU 2019131098 A RU2019131098 A RU 2019131098A RU 2019131098 A RU2019131098 A RU 2019131098A RU 2019131098 A3 RU2019131098 A3 RU 2019131098A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1705484.2A GB201705484D0 (en) | 2017-04-05 | 2017-04-05 | Genetic construct |
| GB1705484.2 | 2017-04-05 | ||
| PCT/GB2018/050824 WO2018185468A1 (en) | 2017-04-05 | 2018-03-28 | Genetic construct for use in the treatment of neurodegenerative disorder or stroke |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2019131098A RU2019131098A (ru) | 2021-05-05 |
| RU2019131098A3 true RU2019131098A3 (cg-RX-API-DMAC7.html) | 2021-07-27 |
| RU2757932C2 RU2757932C2 (ru) | 2021-10-25 |
Family
ID=58682577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019131098A RU2757932C2 (ru) | 2017-04-05 | 2018-03-28 | Генетическая конструкция для применения при лечении нейродегенеративного нарушения или инсульта |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20200046850A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3606546B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7296321B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102616629B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN110809476B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018248651B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3058549A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2881176T3 (cg-RX-API-DMAC7.html) |
| GB (1) | GB201705484D0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2019012000A (cg-RX-API-DMAC7.html) |
| PL (1) | PL3606546T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3606546T (cg-RX-API-DMAC7.html) |
| RU (1) | RU2757932C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018185468A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200057051A (ko) * | 2017-09-27 | 2020-05-25 | 시질론 테라퓨틱스, 인크. | 활성 세포를 포함하는 방법, 조성물 및 이식 가능한 요소 |
| JP2022514863A (ja) * | 2018-12-19 | 2022-02-16 | ヴェルサメブ アーゲー | タンパク質をコードするrna |
| WO2020179844A1 (ja) | 2019-03-04 | 2020-09-10 | 公益財団法人東京都医学総合研究所 | Trk断片をコードする核酸構築物、及びその利用 |
| US12649930B2 (en) | 2019-03-27 | 2026-06-09 | Sigilon Therapeutics, Inc. | Compositions, devices, and methods for treating Fabry disease |
| GB202004832D0 (en) * | 2020-04-01 | 2020-05-13 | Instituto De Medicina Molecular Faculdade De Medicina Univ De Lisboa | Therapeutic agaents, pharmaceutical compositions, and associated biomarkers |
| EP4262846A4 (en) * | 2020-12-18 | 2024-11-20 | Baylor College of Medicine | ADMINISTRATION OF ABETA VARIANTS FOR INHIBITION OF AGGREGATION |
| CN114933657B (zh) * | 2021-08-25 | 2024-02-02 | 上海交通大学医学院 | 神经生长因子突变体重组蛋白及其应用 |
| CN118256562A (zh) * | 2022-12-26 | 2024-06-28 | 科辉智药(深圳)新药研究中心有限公司 | 一种用于中枢神经系统疾病治疗的基因序列构建体及其应用 |
| KR20250142340A (ko) | 2023-02-02 | 2025-09-30 | 퀘세라 리미티드 | 재조합 아데노-부속 바이러스 벡터 |
| EP4413993A1 (en) * | 2023-02-10 | 2024-08-14 | Dompe' Farmaceutici S.P.A. | Method of obtaining recombinant human brain-derived neurotrophic factor |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2588221C (en) * | 1999-06-08 | 2013-07-09 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| US20030124095A1 (en) * | 2001-12-31 | 2003-07-03 | Regents Of The University Of California | Methods for therapeutic use of brain derived neurotrophic factor in the entorhinal cortex |
| US9265843B2 (en) | 2008-03-27 | 2016-02-23 | The Ohio State University | Treatment of metabolic-related disorders using hypothalamic gene transfer of BDNF and compositions therefor |
| EP3165537A1 (en) * | 2008-12-19 | 2017-05-10 | H. Lundbeck A/S | Modulation of the vps 10-domain receptor family for the treatment of mental and behavioural disorders |
| ES2694592T3 (es) * | 2012-03-15 | 2018-12-21 | Curna, Inc. | Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado del cerebro (BDNF) por inhibición del transcrito antisentido natural de BDNF |
| GB2547179A (en) | 2015-10-26 | 2017-08-16 | Quethera Ltd | Genetic construct |
-
2017
- 2017-04-05 GB GBGB1705484.2A patent/GB201705484D0/en not_active Ceased
-
2018
- 2018-03-28 MX MX2019012000A patent/MX2019012000A/es unknown
- 2018-03-28 PT PT187159116T patent/PT3606546T/pt unknown
- 2018-03-28 EP EP18715911.6A patent/EP3606546B1/en active Active
- 2018-03-28 CN CN201880023931.XA patent/CN110809476B/zh active Active
- 2018-03-28 JP JP2019554630A patent/JP7296321B2/ja active Active
- 2018-03-28 PL PL18715911T patent/PL3606546T3/pl unknown
- 2018-03-28 ES ES18715911T patent/ES2881176T3/es active Active
- 2018-03-28 CA CA3058549A patent/CA3058549A1/en active Pending
- 2018-03-28 US US16/497,412 patent/US20200046850A1/en not_active Abandoned
- 2018-03-28 WO PCT/GB2018/050824 patent/WO2018185468A1/en not_active Ceased
- 2018-03-28 RU RU2019131098A patent/RU2757932C2/ru active
- 2018-03-28 AU AU2018248651A patent/AU2018248651B2/en active Active
- 2018-03-28 KR KR1020197032606A patent/KR102616629B1/ko active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7296321B2 (ja) | 2023-06-22 |
| RU2019131098A (ru) | 2021-05-05 |
| US20200046850A1 (en) | 2020-02-13 |
| AU2018248651B2 (en) | 2024-07-25 |
| MX2019012000A (es) | 2020-01-27 |
| RU2757932C2 (ru) | 2021-10-25 |
| GB201705484D0 (en) | 2017-05-17 |
| CN110809476A (zh) | 2020-02-18 |
| JP2020516244A (ja) | 2020-06-11 |
| PL3606546T3 (pl) | 2021-11-08 |
| KR102616629B1 (ko) | 2023-12-21 |
| CA3058549A1 (en) | 2018-10-11 |
| EP3606546B1 (en) | 2021-04-28 |
| WO2018185468A1 (en) | 2018-10-11 |
| KR20200005549A (ko) | 2020-01-15 |
| EP3606546A1 (en) | 2020-02-12 |
| CN110809476B (zh) | 2024-02-27 |
| AU2018248651A1 (en) | 2019-10-17 |
| ES2881176T3 (es) | 2021-11-29 |
| PT3606546T (pt) | 2021-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR122021000189A2 (cg-RX-API-DMAC7.html) | ||
| BR112019008823A2 (cg-RX-API-DMAC7.html) | ||
| BR112019025875B1 (pt) | Sistema de cilindro com estrutura de ocupação de movimento relativo | |
| BR112020011860B1 (pt) | Dispositivo cirúrgico para cortar uma lente dentro de um saco capsular de um olho | |
| BR112020008714B1 (pt) | Uso de medicamentos serotoninérgicos para tratar trombocitopenia induzida por vírus | |
| BR112020006992B1 (pt) | Dispositivo de recolhimento e método para o recolhimento de uma embarcação | |
| BR112019023976B1 (pt) | Sistema e método para comunicar dados de saúde em um ambiente de cuidados de saúde | |
| BR112020003314B1 (pt) | Sistema terapêutico transdérmico para administração transdérmica de um agente ativo, seu método de fabricação, usos de emulsificante, e método para estabilizar uma mistura de revestimento bifásica | |
| BR112020003112B1 (pt) | Método de garantir a viabilidade de uma máquina para uma tarefa agendada | |
| BR112020002577B1 (pt) | Método de melhoria de rendimento de centrifugação dupla para purificação de óleo nutritivo | |
| BR112020001262B1 (pt) | Processo para preparar uma composição de entrega de fármaco | |
| BR112020003569B1 (pt) | Método e disposição para transmissão de dados comutados por pacote entre dispositivos de emissão e recepção marítimos para uma embarcação marítima e dispositivos de emissão e recepção terrestres por interfaces aéreas | |
| BR112020000320B1 (pt) | Dispositivo bioerodível de administração de fármacos, seu método de preparação, e uso de uma folha não-tecido | |
| BR112019016885B1 (pt) | Remodelagem de imagem integrada e codificação de vídeo | |
| BR112019027876B1 (pt) | Método de codificação para uma comunicação sem fio, codificador, método de decodificação, decodificador, aparelho de comunicação, meio de armazenagem legível por computador, e sistema de comunicações | |
| BR112020001354B1 (pt) | Método, em uma primeira estação base, para suportar posicionamento de um dispositivo móvel e primeira estação base para suportar posicionamento de um dispositivo móvel | |
| BR102018011961B1 (pt) | Sistemas, métodos e meio não transitório legível por computador para analisar cores a partir de uma plataforma de mídia social | |
| BR112019026880B1 (pt) | Método de comunicação, método para receber dados, e, dispositivo | |
| BR112019023944B1 (pt) | Combinação farmacêutica para o tratamento de um câncer | |
| BR112019021396B1 (pt) | Processo para fabricação de pululano | |
| BR102018003507B1 (pt) | Sistema de isolamento de tensão de tambor de guincho | |
| BR112019016182B1 (pt) | Método para diagnosticar risco de revisão relacionado a implante | |
| BR112019017156B1 (pt) | Dispositivo, sistema e método de gerenciamento de recepção de pedido, e, meio de armazenamento legível por computador | |
| BR112020006250B1 (pt) | Primeira estação base e método de controle de estado em uma primeira estação base | |
| BR112020009459B1 (pt) | Método para indicar informações de domínio de frequência do conjunto de recursos de controle comum de informações mínimas remanescentes do sistema |